Poster Session A
Saturday, Dec. 1, 2018
4:30–6:30 p.m.

A01 Vps34 promotes macropinocytosis in Tsc2-deficient cells. Charilaos Filippakis, Brigham & Women's Hospital, Boston, MA, USA.

A02 SYK kinase inhibition causes autophagy pathway activation via suppression of mTORC1 in KRAS-mutant pancreatic cancer cells. Kevin Hua, Boston University, Boston, MA, USA.

A03 Autophagy and HSP27: A potential link to define autophagy fate in osteosarcoma. Grace Nehme, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

A04 Interaction of VRK2 with Akt at lysosomes controls induction of autophagy. Masayuki Noguchi, Hokkaido University, Sapporo, Hokkaido, Japan.

A05 Uncovering the role of Vps34 in pancreatic autophagy and its relation to chronic pancreatitis, a risk factor for pancreatic cancer. Fernanda Ramos, INSERM U1037/CRCT, Toulouse, France.

A06, PR09 Targeting glutamine addiction of PIK3CA mutant colorectal cancers: From preclinical models to clinical trials. Zhenghe (John) Wang, Case Western Reserve University, Cleveland, OH, USA.

A07 Role of the class IA PI3K p110β subunit in pancreatic cancer. Silvia Arcucci, INSERM U1037, CRCT, UPS, Toulouse, France.

A08 PI3Kbeta regulates beta-1 integrin signaling in invadopodia through formation of PI(3,4)P2. Jonathan Backer, Albert Einstein College of Medicine, Bronx, NY, USA.

A09 Phosphorylation of mSin1-CRIM domain regulates protein stability and substrate selectivity. Yueh-Ho Chiu, Imperial College London, London, United Kingdom.

A10 Exploring the interplay between the purinosome, a multienzyme, purine biosynthetic machine, and the Rheb-mTORC1 signaling axis. Natasha Emmanuel, Pfizer, Pearl River, NY, USA.

A11, PR05 Regulation of mRNA N6-adenosine methylation by the mTOR signaling. Gina Lee, Weill Cornell Medicine, New York, NY, USA.

A13 Mammalian EAK-7 activates alternative mTOR signaling to regulate cell proliferation and migration. Joe Nguyen, University of Michigan, Ann Arbor, MI, USA.

A14, PR01 Phosphorylation of DEPDC5 by the Pim-1 protein kinase, a cancer driver, stimulates mTORC1 activity by regulating the DEPDC5-Rag GTPase interaction. Sathish Padi, University of Arizona Cancer Center, Tucson, AZ, USA.
A15 The selective role of PIK3CB/p110β in temozolomide resistance in glioblastoma. Kevin Pridham, Virginia Tech Carilion Research Institute, Roanoke, VA, USA.

A16 Suppressor of morphogenesis in genitalia 1 (SMG1) is a novel negative regulator of mammalian target of rapamycin complex 2 (mTORC2). Tara Roberts, Western Sydney University, Sydney, New South Wales, Australia.

A17 Targeting PI3K/Akt-mediated MADD phosphorylation improves TRAIL sensitivity in anaplastic thyroid cancer. Shikha Saini, University of Illinois at Chicago, Chicago, IL, USA.

A18 Selectively targeting PI3K isoforms to treat glioblastoma. Zhi Sheng, Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, VA, USA.

A19, PR04 4EBP1 reactivation by potent and selective bi-steric inhibitors of mTORC1. Nidhi Tibrewal, Revolution Medicines, Redwood City, CA, USA.

A20 Investigating the role of SCO2 in the metabolic adaptation of cancer cells. Oro Uchenunu, McGill University, Montreal, Canada.

A21 Compound PIK3CA mutations support a mutational dose response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer. Neil Vasan, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.

A22 Selective inhibition of TOR complex 2 as a mean to sensitize cancer cells to DNA damage agents?. Ronit Weisman, Open University of Israel, Raanana, Israel.

A23 Dissecting the SMAD4 metastasis suppressor complex to identify novel prognostic biomarkers and therapeutic targets for colon cancer. Chen Khuan Wong, Boston University School of Medicine, Boston, MA, USA.

A24 CD146-Rictor interaction reveals a pathway linking mTORC2 activation with extracellular stimuli. Wenyi Xu, Beijing Advanced Innovation Center for Food Nutrition and Human Health, China Agricultural University, Beijing, China.

A25 Activating alterations of p110 subunits determine PI3K isoform selectivity in prostate cancer. Zeda Zhang, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

A26 mTOR inhibition promotes differentiation of human regulatory T cells via privileged mRNA translation. Viviana Volta, NYU School of Medicine, New York, NY, USA.

A27 The relationship between aspirin and cancer via its inhibition of mTOR pathway. Oyku Ay, Ege University, Izmir, Turkey.
Poster Session A
Saturday, Dec. 1, 2018
4:30–6:30 p.m.

A28 Rapamycin-upregulated miR-29b promotes mTORC1-hyperactivative cell growth by downregulating retinoic acid receptor β (RARβ). Heng-Jia (Tina) Liu, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.

A29 Targeted disruption of PI3K/Akt/mTOR signaling pathway induces cell cycle arrest, apoptosis, autophagy, and inhibits inflammation, invasion, and angiogenesis of OSCC cells. Sadhna Aggarwal, AIIMS, Delhi, India.

A30 Targeting of the mTOR pathway in human acute myeloid leukemia cells using functionalized gold nanoparticles. Inna Yasinska, University of Kent, Chatham Maritime, Kent, United Kingdom.